| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5474979 | ABBVIE | Nonirritating emulsions for sensitive tissue |
May, 2014
(9 years ago) | |
| US8633162 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(4 months from now) | |
| US8648048 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(4 months from now) | |
| US8685930 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(4 months from now) | |
| US9248191 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(4 months from now) | |
| US8642556 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(4 months from now) | |
| US8629111 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(4 months from now) | |
Restasis is owned by Abbvie.
Restasis contains Cyclosporine.
Restasis has a total of 7 drug patents out of which 1 drug patent has expired.
Expired drug patents of Restasis are:
- US5474979
Restasis was authorised for market use on 23 December, 2002.
Restasis is available in emulsion;ophthalmic dosage forms.
Restasis can be used as increase tear production to treat patients with keratoconjunctivitis sicca (dry eye)., increase tear production in patients with keratoconjunctivitis sicca (dry eye)..
The generics of Restasis are possible to be released after 27 August, 2024.
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 23 December, 2002
Treatment: Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).; Increase tear production in patients with keratoconjunctivitis sicca (dry eye).
Dosage: EMULSION;OPHTHALMIC
RESTASIS family patents
